CURRENT NEWS

CNS Network selects ALPHADAS^®, Logos Technologies Early Phase EDC System.
Read more

Spaulding Clinical's Innovations produce best quality in 240 Subject TQT Study.
Read more

Following Omnicomm Systems announcement in the press on 4th August 2009, Logos Holdings Ltd and Logos Technologies Inc were not affected by this and continue to own the Logos EDC assets and proprietary software known as ALPHADAS^® as previously. The Logos group continue to be owned by the same shareholders.

For any enquiries relating to this announcement or ALPHADAS^®, a world leading early phase EDC and Phase I site automation tool, please browse our website or for further information.

‘Duke’s Phase I Trials Go Electronic’ – A report by Barry Mangum, Director of Clinical Pharmacology, Duke Clinical Research Unit, and Associate Clinical Professor of Clinical Pharmacology, Duke University Medical Center.
Read more

Qualia Clinical Services selects ALPHADAS^® for Phase I Clinical Trials.
Read more

Logos wins Best IT Strategy at European Outsourcing Awards 2008.
Read more

Bio IT World - Duke goes with ALPHADAS^® for its early phase trials.
Read more

Duke licenses ALPHADAS^® Logos Technologies EDC software.
Read more

Three levels of integration for Exco Intouch, Logos Technologies, by Deborah Borfitz, eCliniqua.
Read more

OmniComm, Logos in EDC pact by Amy Swinderman, Drug Discovery News.
Read more

Exco InTouch Partners with Logos Technologies to Improve Patient Recruitment in Clinical Trials.
Read more

Omnicomm Systems Inc and Logos Technologies partner to provide superior Electronic Data Capture (EDC) for Phase I-IV clinical trials.
Read more

Comprehensive NeuroScience / Comprehensive Phase One "Advanced technology to benefit patients and sponsors..."
Read more